Sophy Denker
A5058728720- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 diagnosis using AI
- Long-Term Effects of COVID-19
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Liver Diseases and Immunity
- Cancer Immunotherapy and Biomarkers
- Corneal surgery and disorders
- Ocular Surface and Contact Lens
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Corneal Surgery and Treatments
- Respiratory Support and Mechanisms
- CNS Lymphoma Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Sepsis Diagnosis and Treatment
Charité - Universitätsmedizin Berlin
2019-2024
Humboldt-Universität zu Berlin
2019-2024
Freie Universität Berlin
2019-2024
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2021-2024
University of Freiburg
2013
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of disease 139 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts enzyme activities, well untargeted plasma proteomes at 687 sampling points. report an initial spike a systemic inflammatory response, which gradually alleviated followed protein signature indicative tissue repair,...
Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such SOFA APACHE II scores show only limited performance for predicting survival severely ill patients. Additional tools also needed monitor treatment, including experimental therapies clinical trials. Comprehensively capturing human physiology, we speculated that proteomics combination with new...
Abstract Background Increasing evidence suggests that secondary sclerosing cholangitis (SSC), which can lead to cirrhosis or liver failure, may be a hepatobiliary long-term complication of COVID-19. The aim this study was estimate the frequency and outcome COVID-19 sequela identify possible risk factors. Methods This observational study, conducted at University Hospital Charité Berlin Unfallkrankenhaus Berlin, Germany, involved hospitalized patients with pneumonia, including 1082 ventilated...
Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical virological disease trajectories. The purpose this work was to identify risk factors associated with need invasive mechanical ventilation (IMV), analyse viral kinetics patients without IMV provide a comprehensive description course.A cohort 168 hospitalised adult COVID-19 enrolled prospective observational study at large European tertiary care...
Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives this work were to characterize kinetics acute respiratory syndrome 2 (SARS-CoV-2) concentration in upper tract (URT) and antibody response patients with (D+) without (D-) dexamethasone treatment.Data biosamples from hospitalized COVID-19, enrolled between 4th March 11th December 2020 a prospective observational study, analysed....
Abstract COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There an urgent need for predictive markers that can guide decision-making, inform about the effect of experimental therapies, point novel therapeutic targets. Here, we characterize time-dependent progression through different stages disease, by measuring 86 accredited diagnostic parameters plasma proteomes at 687 sampling points, a cohort 139 patients...
BackgroundAny inflammatory response following corneal transplantation may induce rejection and irreversible graft failure. The purpose of this study is to analyze the anti-inflammatory effect azithromycin (AZM) experimental keratoplasty in rats. MethodsCorneal transplants were performed between Fisher-donor Lewis-recipient Recipients postoperatively treated three times daily with AZM, miglyol, ofloxacin or dexamethasone eye drops. As an additional control, AZM was applied syngeneic...
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61–80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ≥2). Patients receive standard chemotherapy (CHOP) plus immunotherapy (Rituximab), biological agent (the proteasome inhibitor Bortezomib) signaling Bruton's Tyrosine Kinase-targeting therapeutic Ibrutinib). Using all-comers approach, but...
Abstract Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such SOFA APACHE II scores show only limited performance for predicting survival severely ill patients. Comprehensively capturing host physiology, we speculated that proteomics combination with new data-driven analysis strategies could produce generation prognostic discriminators. We studied...
Diffuse large B-cell lymphoma (DLBCL) is the most common entity, and its incidence increases with age. There a paucity of data regarding use biweekly R-CHOP (R-CHOP-14) in patients ≥80 years We performed retrospective cohort study DLBCL aged treated R-CHOP-14 R-miniCHOP two academic tertiary centers Germany between 01/01/2005 12/30/2019. Overall, 79 were included. Median age was 84 (range 80-91). Despite higher CR rates (71.4% vs. 52.4%), no statistically significant difference could be...
Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30–40% of patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many them experience relapse eventually succumb to their disease. Enhancing first-line efficacy in at higher risk, among elderly, key improve long-term outcomes. Numerous attempts combine R-CHOP with targeted agents failed large randomized phase III trials. The addition Ibrutinib enhanced survival younger...